Jane Chung - 09 Aug 2022 Form 4 Insider Report for SUTRO BIOPHARMA, INC. (STRO)

Role: Chief Commercial Officer
Signature: /s/ Edward C. Albini as attorney-in-fact for Jane Chung
Issuer symbol: STRO
Transactions as of: 09 Aug 2022
Net transactions value: -$42,788
Form type: 4
Filing time: 10 Aug 2022, 18:16:37 UTC
Previous filing: 07 Mar 2022
Next filing: 11 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	STRO	Common Stock	Options Exercise	$0	+18,750	+750%	$0.000000	21,250	09 Aug 2022	Direct	F1
transaction	STRO	Common Stock	Tax liability	$42,788	-6,483	-31%	$6.60	14,767	09 Aug 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	STRO	Restricted Stock Unit (RSU)	Options Exercise	$0	-18,750	-25%	$0.000000	56,250	09 Aug 2022	Common Stock	18,750		Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 2,500 shares acquired under the issuer's employee stock purchase plan on March 15, 2022.
F2	Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person.
F3	Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F4	The RSUs vest as to 1/4th of the total shares annually beginning on August 9, 2022, subject to the reporting person's provision of service to the issuer on each vesting date.